These terms can be broadly classified into the following categories: clinical applications (eg, NSCLC, CML, renal cell carcinoma, lung adenocarcinoma), genetic studies (eg, EGFR, EGFR mutation, BCR-ABL), typical drugs (eg, erlotinib, imatinib, gefitinib, sunitinib, afatinib, dasatinib, osimertinib, nilotinib), and chemotherapy and drug resistance (eg, targeted therapy, resistance, chemotherapy, drug resistance). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.